Current whole-body MRI applications in the neurofibromatosis

NF1, NF2, and schwannomatosis

Shivani Ahlawat, Laura M Fayad, Muhammad Shayan Khan, Miriam A. Bredella, Gordon J. Harris, D. Gareth Evans, Said Farschtschi, Michael Jacobs, Avneesh Chhabra, Johannes M. Salamon, Ralph Wenzel, Victor F. Mautner, Eva Dombi, Wenli Cai, Scott R. Plotkin, Jaishri Blakeley

Research output: Contribution to journalArticle

Abstract

Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials. Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy. Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection ofWBtumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility. Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI.

Original languageEnglish (US)
Pages (from-to)S31-S39
JournalNeurology
Volume87
Issue number7
DOIs
StatePublished - Aug 16 2016

Fingerprint

Sequence Inversion
Neurofibromatosis 2
Neurofibromatoses
Neurofibromatosis 1
Tumor Burden
Neoplasms
Clinical Trials
Technology
Schwannomatosis
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Current whole-body MRI applications in the neurofibromatosis : NF1, NF2, and schwannomatosis. / Ahlawat, Shivani; Fayad, Laura M; Khan, Muhammad Shayan; Bredella, Miriam A.; Harris, Gordon J.; Evans, D. Gareth; Farschtschi, Said; Jacobs, Michael; Chhabra, Avneesh; Salamon, Johannes M.; Wenzel, Ralph; Mautner, Victor F.; Dombi, Eva; Cai, Wenli; Plotkin, Scott R.; Blakeley, Jaishri.

In: Neurology, Vol. 87, No. 7, 16.08.2016, p. S31-S39.

Research output: Contribution to journalArticle

Ahlawat, S, Fayad, LM, Khan, MS, Bredella, MA, Harris, GJ, Evans, DG, Farschtschi, S, Jacobs, M, Chhabra, A, Salamon, JM, Wenzel, R, Mautner, VF, Dombi, E, Cai, W, Plotkin, SR & Blakeley, J 2016, 'Current whole-body MRI applications in the neurofibromatosis: NF1, NF2, and schwannomatosis', Neurology, vol. 87, no. 7, pp. S31-S39. https://doi.org/10.1212/WNL.0000000000002929
Ahlawat, Shivani ; Fayad, Laura M ; Khan, Muhammad Shayan ; Bredella, Miriam A. ; Harris, Gordon J. ; Evans, D. Gareth ; Farschtschi, Said ; Jacobs, Michael ; Chhabra, Avneesh ; Salamon, Johannes M. ; Wenzel, Ralph ; Mautner, Victor F. ; Dombi, Eva ; Cai, Wenli ; Plotkin, Scott R. ; Blakeley, Jaishri. / Current whole-body MRI applications in the neurofibromatosis : NF1, NF2, and schwannomatosis. In: Neurology. 2016 ; Vol. 87, No. 7. pp. S31-S39.
@article{40e7c91dde9440b9a1518c6f799aa5c5,
title = "Current whole-body MRI applications in the neurofibromatosis: NF1, NF2, and schwannomatosis",
abstract = "Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials. Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy. Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection ofWBtumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility. Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI.",
author = "Shivani Ahlawat and Fayad, {Laura M} and Khan, {Muhammad Shayan} and Bredella, {Miriam A.} and Harris, {Gordon J.} and Evans, {D. Gareth} and Said Farschtschi and Michael Jacobs and Avneesh Chhabra and Salamon, {Johannes M.} and Ralph Wenzel and Mautner, {Victor F.} and Eva Dombi and Wenli Cai and Plotkin, {Scott R.} and Jaishri Blakeley",
year = "2016",
month = "8",
day = "16",
doi = "10.1212/WNL.0000000000002929",
language = "English (US)",
volume = "87",
pages = "S31--S39",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Current whole-body MRI applications in the neurofibromatosis

T2 - NF1, NF2, and schwannomatosis

AU - Ahlawat, Shivani

AU - Fayad, Laura M

AU - Khan, Muhammad Shayan

AU - Bredella, Miriam A.

AU - Harris, Gordon J.

AU - Evans, D. Gareth

AU - Farschtschi, Said

AU - Jacobs, Michael

AU - Chhabra, Avneesh

AU - Salamon, Johannes M.

AU - Wenzel, Ralph

AU - Mautner, Victor F.

AU - Dombi, Eva

AU - Cai, Wenli

AU - Plotkin, Scott R.

AU - Blakeley, Jaishri

PY - 2016/8/16

Y1 - 2016/8/16

N2 - Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials. Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy. Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection ofWBtumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility. Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI.

AB - Objectives: The Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration Whole-Body MRI (WB-MRI) Working Group reviewed the existing literature on WB-MRI, an emerging technology for assessing disease in patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2), and schwannomatosis (SWN), to recommend optimal image acquisition and analysis methods to enable WB-MRI as an endpoint in NF clinical trials. Methods: A systematic process was used to review all published data about WB-MRI in NF syndromes to assess diagnostic accuracy, feasibility and reproducibility, and data about specific techniques for assessment of tumor burden, characterization of neoplasms, and response to therapy. Results: WB-MRI at 1.5T or 3.0T is feasible for image acquisition. Short tau inversion recovery (STIR) sequence is used in all investigations to date, suggesting consensus about the utility of this sequence for detection ofWBtumor burden in people with NF. There are insufficient data to support a consensus statement about the optimal imaging planes (axial vs coronal) or 2D vs 3D approaches. Functional imaging, although used in some NF studies, has not been systematically applied or evaluated. There are no comparative studies between regional vs WB-MRI or evaluations of WB-MRI reproducibility. Conclusions: WB-MRI is feasible for identifying tumors using both 1.5T and 3.0T systems. The STIR sequence is a core sequence. Additional investigation is needed to define the optimal approach for volumetric analysis, the reproducibility of WB-MRI in NF, and the diagnostic performance of WB-MRI vs regional MRI.

UR - http://www.scopus.com/inward/record.url?scp=85003723261&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003723261&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000002929

DO - 10.1212/WNL.0000000000002929

M3 - Article

VL - 87

SP - S31-S39

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 7

ER -